TEL AVIV, Israel and BETHESDA, Maryland, July 11, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that senior members of its team will be attending the National Cannabis Industry Association Business Conference and Expo, to be held in San Jose convention center, California, USA, on July 25th-27th 2018, and will be available for one on one meetings.
The National Cannabis Industry Association, or NCIA, is the industry’s premier organization in the United States, and the Business conference and expo held in San Jose is their 5th and largest event to date. The event brings together professionals in various fields within the cannabis sector in the USA.
In attendance will be Mr. Eyal Barad, Co-Founder and CEO, alongside Mr. Noam Permont, VP of Business Development.
Eyal Barad, CEO of the company, said: “We are looking forward to meeting and collaborating with fellow cannabis industry members. Considering the recent approval of a cannabis-based medicine by the FDA, we believe that our ability to network and collaborate in this evolving environment will prove instrumental to our efforts to introduce additional cannabis-based medicines and therapies into mainstream medicine in the future.”
Mr. Barad and Mr. Permont will be accepting 1 on 1 meetings and are available at [email protected]
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is developing a blood test that allows practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient’s profile and cancer. Cannabics’ approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative, the way it’s being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies. The company’s R&D is based in Israel, where it is licensed to conduct scientific and clinical research on harnessing the therapeutic properties of cannabinoid formulations.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 6th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.